CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5,809 enrolled
Drug / intervention
VITAL modelbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04527874
NCT04527874N/ACompleted

Assessment of a Viral Load Result-driven Automated Differentiated Service Delivery Model for Participants Taking Antiretroviral Therapy in Lesotho

Swiss Tropical & Public Health Institute·interventional·Posted Aug 27, 2020·Updated Aug 1, 2025

In Brief

A clinical study evaluating VITAL model for HIV Infections. Completed, enrolled 5,809 participants across 18 sites.

Detailed Summary

This cluster randomized clinical trial at 18 nurse-led rural health centers in Lesotho will test an automated differentiated service delivery model using viral load results, other clinical characteristics and participants' preference to automatically triage participants into groups requiring different levels of attention and care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesLesotho
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 27, 2020
Enrollment StartOct 14, 2020
Primary CompletionAug 7, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.8 years ago

Interventions

VITAL modelbehavioral

The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform. To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening.